Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Can genes determine complex traits?
- The human genetics
- Genetic variation
- Pharmacogenetics
- Genetically based optimization of drug dosing
- Variations in drug response
- Genetic polymorphisms
- Polymorphic and polygenic effects on drug action
- Examples of pharmacogenetics
- Pharmacogenetics of mood disorders
- Present and future
- Is antidepressant response genetically controlled?
- Pharmacogenetic studies (Medline 1998-2004)
- Genes involved in response to antidepressants
- Serotonin transporter
- Serotonin transporter polymorphism
- Regulatory variant of 5-HT transporter
- Serotonin and psychopathology
- Serotonin transporter and depression
- Serotonin transporter and other mood disorders
- 5-HTTLPR and response to fluvoxamine
- HAMD decrease during fluvoxamine treatment
- SERT studies in Caucasians
- SERT studies in Orientals
- A new polymorphism (A-G) within SERTPR
- Serotonin transporter promoter (Nakamura, 2000)
- Variants of long and short repeats
- Types of 16th repeat (*l)
- SERTPR *l and *s allele variants
- Review - pharmacogenetics and antidepressants
- Genes investigated in the short term
- Serotonin receptor 1A studies
- Serotonin receptor 1A
- G-protein beta 3 subunit studies
- G-protein beta 3 subunit
- Serotonin receptor 2A studies
- Tryptophan hydroxylase
- Tryptophan hydroxylase studies
- Polymorphism and antidepressant response
- Studies with positive but unreplicated results
- Sufficiency criteria for clinical prediction
- Negative studies
- Polymorphisms in FKBP5
- FKBP5 genotype and depression
- Methods - procedures
- Do genetic patterns influence drug response only?
- Time course
- Most studies focus on the first weeks of treatment
- Example for follow-up study
- Illness time course
- 6-month follow-up study
- A follow-up study: methods
- Towards new classification of psychiatric disorders
- Is antidepressant response a unitary phenomenon?
- CLOCK gene
- Insomnia and CLOCK gene polymorphism
- CLOCK gene polymorphism
- CLOCK variants and insomnia during treatment
- CC variant resist insomnia improvement
- CLOCK variant in a follow-up study
- UP and BP subject with *C allele
- New classification of psychiatric disorders
- How do genes exert their role?
- PER gene
- PER gene characteristics
- Association with anti-depressant efficacy
- PER gene and clinical features
- PER gene and depressive symptoms
- PER gene and personality
- PER gene and social impairment
- Broad influence of PER gene
- Less common PER gene variants
- Summary of gene influences
- Complex gene direct and indirect effects?
- Novelty seeking (NS) trait
- Temperament and character in mood disorders
- Short variant of SERT has less NS
- Would be the puzzle the actual image of reality?
- Pharmacogenetics: problematic issues
- Neural network analysis
- Neural network analysis in pharmacogenetics
- Neural network analysis techniques
- Neural network analysis gives more details
- HTT, TPH - MLP
- Technical details on MLP
- ROC curve of the analysis
- The significance of the network
- Comparison with traditional techniques
- Neural network analysis summary
- Conclusion
- Ethical, legal and social implications
- 2012 update - introduction
- Pooling Caucasians and Asians separately
- HTTLPR - conclusions
- Effects in people with short variant (1)
- Effects in people with short variant (2)
- Broad influence of a single gene
- Genome wide associations - studies
- Other genes involved in antidepressant
- Main replicated genes
Topics Covered
- Pharmacogenetic studies in mood disorder
- Candidate genes as possible genetic predictors of antidepressant response efficacy
- Serotonin transporter gene (5-HTTLPR)
- Serotonin receptor 1A (5HT1A-C-1019G)
- G-protein beta3-subunit (Gbeta3-C825T)
- Serotonin receptor 2A (5HT2A
- 102TC)
- Tryptophan hydroxylase gene (TPH-A218C)
- Associations for FKBP5 and other unreplicated gene variants
- Follow up pharmacogenetic studies
- Circadian Locomotor Output Cycles Kaput (CLOCK-T3111C) gene variants are associated with insomnia and other features
- PER 15 variants and mood disorder phenotypes
- Neural networks: the example of 5-HTTLPR and TPH polymorphisms
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Serretti, A. (2012, December 1). Genetic polymorphisms influencing the response of antidepressants [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 25, 2024, from https://doi.org/10.69645/NWWD8346.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Alessandro Serretti has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.